Cardioprotective effect of atorvastatin alone or in combination with remote ischemic preconditioning on the biochemical changes induced by ischemic/reperfusion injury in a mutual prospective study with a clinical and experimental animal arm
Autor: | Safaa Y. Salem, Sabah A. Fadil, Ayman K.M. Hassan, Amira F. Taha, Ehab S. El Desoky |
---|---|
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Adult Male Adolescent medicine.medical_treatment Atorvastatin Ischemia Myocardial Ischemia Myocardial Reperfusion Injury 030204 cardiovascular system & hematology Nitric Oxide 03 medical and health sciences Young Adult 0302 clinical medicine Troponin I medicine Animals Humans Prospective Studies Ischemic Preconditioning Aged Aged 80 and over business.industry Percutaneous coronary intervention Middle Aged medicine.disease Disease Models Animal 030104 developmental biology Losartan C-Reactive Protein Treatment Outcome Anesthesia Conventional PCI Ischemic preconditioning Cytokines Female Rabbits Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business Reperfusion injury Biomarkers medicine.drug Follow-Up Studies |
Zdroj: | International journal of cardiology. 222 |
ISSN: | 1874-1754 |
Popis: | Atorvastatin and remote ischemic preconditioning (RIPC) have beneficial cardiovascular protective effects. The aim of the study was to investigate possible effect of this drug alone and in combination with RIPC on the biochemical changes induced by ischemic/reperfusion injury (I/R) in a combined study with a clinical and experimental animal arm.Thirty consecutive patients undergoing elective percutaneous coronary intervention (PCI) were divided into three groups (10 each): group I (control group without any preconditioning), group II (patients who were maintained on atorvastatin (80mg/day) for one month before PCI), and group III (similar to group II but PCI was preceded by RIPC). On the other hand, sixty adult male New Zealand white rabbits were divided into 6 groups (10 each): group I (control), group II (sham), group III (I/R as 30min ischemia followed by 120min reperfusion), group IV (regular atorvastatin 10mg/kg for 40days orally followed by I/R), group V (I/R preceded by RIPC) and group VI (similar to group IV but I/R was preceded by RIPC). Tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), nitric oxide (NO), troponin I (cTnI), creatine kinase MB (CK-MB) and C-reactive protein (CRP) were measured in blood for all study groups.Clinical and experimental parts showed that groups with RIPC combined with atorvastatin pre-treatment showed a synergistic protective effect against I/R injury as evidenced by significant reduction (P0.001) in the levels of TNF-α, cTnI (in patients) and IL-6, CK-MB and CRP (in rabbits) while the level of NO was significantly (P0.001) increased compared with other groups.Pretreatment with atorvastatin combined with RIPC can exert a synergistic cardioprotective effects by reducing the possible biochemical changes related to ischemic reperfusion injury. |
Databáze: | OpenAIRE |
Externí odkaz: |